Nature: Great discoveries! A human antibody can be neutralised against a variety of coronaviruses, including SARS-CoV and SARS-CoV-2

In a new study, researchers from Switzerland Humabs Biomedical, Inc(HumabsBiomedSA) and the University of Washington's2020 May 19 News /BioValleyBIOON / --- We found in 2003 from a severe acute respiratory syndrome (SARS, commonly known as atypical pneumonia) an antibody blood sample from a patient for the first time identified inhibit associated coronavirus, including the lead in 2019 coronavirus disease (COVID- 19) the novel coronavirus SARS-CoV-2This antibody is currently known as S309 (hereinafter referred Vir companies) in Vir biotechnology company has entered a rapid development and test track, the next step may beclinical trialsResearch results in 2020, published online May 18 in the journal Nature, the paper entitled "Cross-neutralizationofSARS-CoVandSARS-CoV2byahumanmonoclonalantibody"Paper corresponding author for the University of Washington School of Medicine assistant professor of biochemistry and DavidVeesler Vir subsidiary Humabs biomedical company DavideCortiThe first author of the paper is Humabs biomedical company DoraPinto and MartinaBeltramello, and Veesler laboratory Young-JunPark and LexiWallsStructure and function of the first author of this paper four years has been studying a variety of coronavirus infection of the complexCryogenic electron microscopy structure of the complexSARS-CoV-2 mAbFab spike protein fragments forming the S309, images from Nature, 2020, doi: 10.1038 / s41586-020-2349- yVeesler said, "We still need to prove that this antibody has a protective effect in living systems, which is so far not done yet."he added" there has not been approved tools or therapeutic agents to obtain permission has been shown to lead to COVID-19 against the coronavirus"If this antibody has been shown to fight the new coronavirus SARS-CoV-2 in humans, it may be become part of the arsenal of the pandemic Veesler said his lab is not the only use of a neutralizing antibody treatment COVID-19 laboratory seek The difference of this antibody is that its people are not looking at COVID-19 patients, but 17 years ago during the SARS epidemic infected the body Veesler said, "Compared with other research team, which is why we can make progress so quickly." researchers identified several from memory B cells in SARS survivors the monoclonal antibody of interest Memory B cells are formed after suffering of an infectious disease Their lineage can persist, sometimes there can be a lifetime They usually remember a pathogen or pathogens like it, and it initiated infection antibody defense again Targeting of a protein structure on the surface of the memory B cells coronavirus SARS survivors of several antibodies: a spike protein (S protein) trimer This structure can identify ACE2 coronavirus receptors on the host cell surface, and their fusion with genetic material is injected into a host cell capacity is essential Such infectious complex (S aforementioned protein trimer) located coronavirus spike structure S309 antibodies into host cells to promote coronavirus spike protein S protein in a targeted and have lost function particularly potent It is capable of binding to the SARS-CoV-2 and virus S protein fragments by the host cell in the vicinity of the attachment site by cryogenic electron microscopy studies and in binding experiments testing, researchers learned S309 a binding site on the antibody recognizes a surface coronavirus, this binding site in a number of β coronavirus virus subgenus sarbocovirus It is conserved, not just in the SARS-CoV (cause of SARS coronavirus), and SARS-CoV-2 virus is conserved This is probably why this is not only for coronavirus antibodies but rather a variety of work-related coronavirus the other weaker antibody to a SARS patient rehabilitation after S309 antibody found in combination, may enhance the neutralizing effect on the SARS-CoV-2 virus researchers said method a mixture of such antibodies may help limit the ability of mutant coronavirus formed such that they can not escape the individual therapeutic antibody The researchers say they hope these preliminary results can be used as preventive measures at high risk of exposure to SARS-CoV-2 alone or in a mixture of S309 antibody, or as a post-exposure treatment of severe restrictions or Drug disease pave the way (Biovalley Bioon.com) reference: 1.DoraPintoetal Cross-neutralizationofSARS-CoV-2byahumanmonoclonalSARS- CoVantibody .Nature, 2020, doi: 10.1038 / s41586-020-2349-y 2.AntibodyneutralizesSARSandCOVID-19coronaviruses https://medicalxpress.com/news/2020 -05-antibody-neutralizes-sars-covid-coronaviruses.html